These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 1357108)

  • 1. Quinine in Acute Rheumatism.
    Med Exam (Phila); 1848 May; 4(41):330-331. PubMed ID: 38120913
    [No Abstract]   [Full Text] [Related]  

  • 2. Quinine in Acute Rheumatism.
    Med Exam (Phila); 1846 Aug; 2(20):510. PubMed ID: 38120293
    [No Abstract]   [Full Text] [Related]  

  • 3. On the Influence of Large Doses of Quinine in Neuralgia.
    Hogg C
    West J Med Surg; 1851 Feb; 7(2):148-150. PubMed ID: 38209809
    [No Abstract]   [Full Text] [Related]  

  • 4. Large Doses of Quinine in Epilepsy.
    Med Exam (Phila); 1844 Oct; 7(21):251. PubMed ID: 38122383
    [No Abstract]   [Full Text] [Related]  

  • 5. Thermal dewetting tunes surface enhanced resonance Raman scattering (SERRS) performance.
    Andrikaki S; Govatsi K; Yannopoulos SN; Voyiatzis GA; Andrikopoulos KS
    RSC Adv; 2018 Aug; 8(51):29062-29070. PubMed ID: 35547969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonspecifically enhanced therapeutic effects of vincristine on multidrug-resistant cancers when coencapsulated with quinine in liposomes.
    Xu Y; Qiu L
    Int J Nanomedicine; 2015; 10():4225-37. PubMed ID: 26170660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
    Greenberg PL; Lee SJ; Advani R; Tallman MS; Sikic BI; Letendre L; Dugan K; Lum B; Chin DL; Dewald G; Paietta E; Bennett JM; Rowe JM
    J Clin Oncol; 2004 Mar; 22(6):1078-86. PubMed ID: 15020609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer: a single disease with a multitude of manifestions?
    Grandics P
    J Carcinog; 2003 Nov; 2(1):9. PubMed ID: 14624698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
    Bardelmeijer HA; van Tellingen O; Schellens JH; Beijnen JH
    Invest New Drugs; 2000 Aug; 18(3):231-41. PubMed ID: 10958591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising approaches in acute leukemia.
    Cortes J; Kantarjian HM
    Invest New Drugs; 2000 Feb; 18(1):57-82. PubMed ID: 10830141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular drug efflux and reversal therapy of cancer.
    Wigler PW
    J Bioenerg Biomembr; 1996 Jun; 28(3):279-84. PubMed ID: 8807402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.
    Julia AM; Roché H; Berlion M; Lucas C; Milano G; Robert J; Bizzari JP; Canal P
    Br J Cancer; 1994 May; 69(5):868-74. PubMed ID: 8180016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance in cancer chemotherapy.
    Patel NH; Rothenberg ML
    Invest New Drugs; 1994; 12(1):1-13. PubMed ID: 7960599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat.
    Van de Vrie W; Jonker AM; Marquet RL; Eggermont AM
    J Cancer Res Clin Oncol; 1994; 120(9):533-8. PubMed ID: 7913932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
    Solary E; Caillot D; Chauffert B; Casasnovas RO; Dumas M; Maynadie M; Guy H
    J Clin Oncol; 1992 Nov; 10(11):1730-6. PubMed ID: 1357108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
    Solary E; Witz B; Caillot D; Moreau P; Desablens B; Cahn JY; Sadoun A; Pignon B; Berthou C; Maloisel F; Guyotat D; Casassus P; Ifrah N; Lamy Y; Audhuy B; Colombat P; Harousseau JL
    Blood; 1996 Aug; 88(4):1198-205. PubMed ID: 8695837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
    List AF; Spier C; Greer J; Wolff S; Hutter J; Dorr R; Salmon S; Futscher B; Baier M; Dalton W
    J Clin Oncol; 1993 Sep; 11(9):1652-60. PubMed ID: 8102639
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.